UPCC 31216: Phase I/II Trial of Regorafenib Hydroxychloroquine and Entinostat in Metastatic Colorectal Cancer

UPCC 31216: Phase I/II Trial of Regorafenib  Hydroxychloroquine  and Entinostat in Metastatic Colorectal Cancer

Brief description of study

The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: - 99 Years
  • Gender: All
Updated on 30 Jan 2020. Study ID: 827226

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center